(Q45800725)

16 December 2017

title

Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer (English)

1 reference

16 December 2017

1 reference

1 reference

3

1 reference

16 December 2017

Laura J. Havrilesky

6

Laura J Havrilesky

1 reference

16 December 2017

Angeles Alvarez Secord

2

Angeles Alvarez Secord

1 reference

16 December 2017

Evan R Myers

5

Evan R Myers

1 reference

16 December 2017

Charles A Leath

4

Charles A Leath

1 reference

16 December 2017

author name string

Jason C Barnett

1

1 reference

16 December 2017

language of work or name

English

0 references

publication date

6 August 2013

1 reference

16 December 2017

published in

Cancer

1 reference

16 December 2017

volume

119

1 reference

16 December 2017

issue

20

1 reference

16 December 2017

page(s)

3653-3661

1 reference

16 December 2017

Incorporation of bevacizumab in the primary treatment of ovarian cancer

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28283

A phase 3 trial of bevacizumab in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28283

At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28283

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28283

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28283

A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28283

Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28283

Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28283

Will evidence ever be sufficient to resolve the challenge of cost containment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28283

Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28283

VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28283

Circulating endothelial progenitors and CXCR4-positive circulating endothelial cells are predictive markers for bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28283

Predictive value of loci in VEGF pathway genes in bevacizumab treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28283

Improved curve fits to summary survival data: application to economic evaluation of health technologies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28283

Incremental expenditure of treating hypertension in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28283

Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28283

The Health Utilities Index (HUI): concepts, measurement properties and applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28283

An empiric estimate of the value of life: updating the renal dialysis cost-effectiveness standard

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28283

Efficient and cost effective population resequencing by pooling and in-solution hybridization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28283

Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28283

Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28283

Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28283

Bevacizumab toxicities and their management in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28283

Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28283

7 January 2021

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28283

7 January 2021

Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28283

7 January 2021

Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28283

7 January 2021

Identifiers

DOI

10.1002/CNCR.28283

1 reference

16 December 2017

1 reference

16 December 2017